These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18289065)

  • 1. Small molecules anti-HIV therapeutics targeting CXCR4.
    Grande F; Garofalo A; Neamati N
    Curr Pharm Des; 2008; 14(4):385-404. PubMed ID: 18289065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
    Seibert C; Sakmar TP
    Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
    De Clercq E; Schols D
    Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
    Esté JA; Cabrera C; De Clercq E; Struyf S; Van Damme J; Bridger G; Skerlj RT; Abrams MJ; Henson G; Gutierrez A; Clotet B; Schols D
    Mol Pharmacol; 1999 Jan; 55(1):67-73. PubMed ID: 9882699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
    Princen K; Schols D
    Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
    Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
    Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-receptor antagonists as HIV-1 entry inhibitors.
    Shaheen F; Collman RG
    Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CXCR4 in HIV cell-entry inhibition.
    Steen A; Schwartz TW; Rosenkilde MM
    Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates.
    Khan A; Greenman J; Archibald SJ
    Curr Med Chem; 2007; 14(21):2257-77. PubMed ID: 17896975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
    De Clercq E
    Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of CXCR4 antagonists in the treatment of HIV.
    Fujii N; Nakashima H; Tamamura H
    Expert Opin Investig Drugs; 2003 Feb; 12(2):185-95. PubMed ID: 12556213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents.
    Scozzafava A; Mastrolorenzo A; Supuran CT
    J Enzyme Inhib Med Chem; 2002 Apr; 17(2):69-76. PubMed ID: 12420752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.
    Vermeire K; Schols D
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1199-212. PubMed ID: 16185162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy.
    Grande F; Occhiuzzi MA; Rizzuti B; Ioele G; De Luca M; Tucci P; Svicher V; Aquaro S; Garofalo A
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30717348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
    Singh IP; Chauthe SK
    Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promising anti-HIV therapeutic strategy with a small molecule CXCR4 antagonist.
    Schols D
    Verh K Acad Geneeskd Belg; 1999; 61(4):551-64. PubMed ID: 10500476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and evaluation of a CXCR4 targeting peptide 4DV3 as an HIV entry inhibitor and a ligand for targeted drug delivery.
    Heon Lee I; Palombo MS; Zhang X; Szekely Z; Sinko PJ
    Eur J Pharm Biopharm; 2019 May; 138():11-22. PubMed ID: 29894816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
    Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
    J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Deep lung--cellular reaction to HIV].
    Tavares Marques MA; Alves V; Duque V; Botelho MF
    Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
    Tamamura H; Tsutsumi H; Fujii N
    Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.